LYRA

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer

Retrieved on: 
Monday, September 13, 2021
Business, Therapy, LYRA, Cornell University, Pharmacotherapy, Nose, FDA, Lists of disasters, Technology, Cantor Fitzgerald, Tissue, Failure, Patient, CRS, Economics, Company, Private Securities Litigation Reform Act, Nasdaq, Public relations, LinkedIn, ENT, Columbia Business School, Legislation, COVID-19, Mergers and acquisitions, RBC Capital Markets, Lehman Brothers, Bear Stearns, Twitter, Ear, GLOBE, Sinusitis, Barclays Investment Bank, Pharmaceutical industry, Management

WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the appointment of Jason Cavalier as Chief Financial Officer, effective today.

Key Points: 
  • WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the appointment of Jason Cavalier as Chief Financial Officer, effective today.
  • Mr. Cavalier is a highly experienced investment banker with extensive background in originating and executing financial transactions, particularly mergers and acquisitions.
  • Jason brings over two decades of expertise in investment banking and corporate strategy and we are excited to welcome him to Lyra Therapeutics leadership team, said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra.
  • Lyra Therapeutics, Inc.is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

Retrieved on: 
Thursday, September 9, 2021

WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that preclinical data for XTreo™ were published online in the peer-review journal, American Journal of Rhinology & Allergy. The manuscript titled, “Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses,” can be accessed online here.

Key Points: 
  • The pharmacokinetics and drug release study evaluated the release of mometasone furoate (MF), a potent anti-inflammatory corticosteroid formulated into Lyras proprietary XTreo matrix, in a rabbit model.
  • XTreo is a powerful drug delivery platform that can target a precise dose of a therapeutic agent consistently over an extended period of time, up to many months.
  • Lyras XTreo technology platform enables precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.
  • The study evaluated the in vitro drug release and in vivo pharmacokinetics of novel XTreo MF matrices in a rabbit dorsal maxillary osteotomy model.

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Tuesday, September 7, 2021

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyras President and Chief Executive Officer, will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.

Key Points: 
  • WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyras President and Chief Executive Officer, will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.
  • The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m.
  • A webcast of the virtual presentation will be available in the Investor Relations section of the Companys website at https://investors.lyratherapeutics.com .
  • Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

Retrieved on: 
Tuesday, August 17, 2021
McGovern Medical School, Company, University, Feinberg School of Medicine, Legislation, Twitter, LYRA, Sinusitis, Therapy, Lists of disasters, ENT, Investor relations, GLOBE, Ear, SEC, Physician, Lyra, Tissue, Nasdaq, Private Securities Litigation Reform Act, Doctor of Philosophy, Research, Data monitoring committee, FARS, CRS, Pharmacotherapy, Nose, Failure, Patient, LinkedIn, FDA, FACS, COVID-19, Department, Professor, MD, Medical device, Pharmaceutical industry

WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host Chronic Rhinosinusitis (CRS) Key Opinion Leader Event on Tuesday, August 31, 2021 from 3:00 p.m. - 4:30 p.m.

Key Points: 
  • WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host Chronic Rhinosinusitis (CRS) Key Opinion Leader Event on Tuesday, August 31, 2021 from 3:00 p.m. - 4:30 p.m.
  • Dr. Luong will be a Coordinating Principal Investigator in one of the LYR-210 Phase 3 clinical trials.
  • Dr. Brent Senior, MD, FACS, FARS, Professor and Vice Chair of Otolaryngology at University of North Carolinas School of Medicine.
  • Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments

Retrieved on: 
Monday, August 9, 2021
Nose, Private Securities Litigation Reform Act, GLOBE, COVID-19, Lyra, FDA, Failure, Therapy, Sinusitis, NDA, Nasdaq, Treatment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacotherapy, Partnership, LYRA, Tissue, ID, ENT, Patient, SEC, LinkedIn, Ear, Lists of disasters, Safety, Legislation, Doctor of Philosophy, Investor relations, Food, China, Twitter, Research, Company, Medical device, Pharmaceutical industry, Lithium

WATERTOWN, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the quarter ended June 30, 2021, and highlighted recent accomplishments.

Key Points: 
  • The Company announced positive topline results of a pharmacokinetic (PK) study of LYR-210 in patients with CRS.
  • General and administrative expenses for the second quarter 2021 were $3.6 million compared to $2.4 million for the same period in 2020.
  • Net loss for the second quarter was $11.0 million compared to $4.5 million for the same period in 2020.
  • To access the live webcast of the call, please visit the Investor Relations section of the Lyra Therapeutics website at https://investors.lyratherapeutics.com/ .